ozanimod surrogate (RP-101074) / BMS - LARVOL DELTA

S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration. (PubMed, Front Immunol) - "In this study, the S1PR-1/-5 modulator RP-101074 was evaluated as a surrogate for ozanimod in the non-inflammatory, primary degenerative animal model of light-induced photoreceptor loss (LI-PRL) in CX3CR1-GFP mice to assess potential neuroprotective effects, independent of its immunomodulatory mechanism of action. Additionally, the myelination status and the quantity of neural stem cells in the optic nerve suggest that RP-101074 may play a role in the activation and/or recruitment of neural stem cells and oligodendrocyte progenitor cells, respectively. The data from our study suggest that RP-101074 may have a broader role in MS treatment beyond immunomodulation, potentially offering a novel approach to mitigate neurodegeneration, a core contributor to chronic disability in MS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Solid Tumor • CX3CR1

Neuroprotective effects of RP-101074 in a preclinical, non-inflammatory neurodegeneration animal model (ECTRIMS 2022) - "Therapeutic RP-101074 treatment shows a neuroprotective effect in the preclinical, non-inflammatory Li-PRL animal model."

Preclinical • CNS Disorders • Immune Modulation • Inflammation • Multiple Sclerosis • Ophthalmology • CX3CR1 • S1PR1

Novel Expert Perspectives in Treating Moderate-to-Severe Ulcerative Colitis - Episode 10: Ozanimod in Ulcerative Colitis (HCPLive) - "Ellen J. Scherl, MD: This is a phase 3 study that achieved clinically meaningful improvement in endoscopic mucosal healing as well as steroid-free remission....Britta Siegmund, MD, et al,showed the rapidity of onset, with a 2-week response in patients who had a response, and a 5-week response with those who were in clinical remission. Miguel Regueiro, MD: Nice overview on ozanimod, this new mechanism of action, first in its class showing that there is benefit in the moderate to severe UC study. Nice job outlining the overall data related to True North and some of the more recent data on rapidity of onset with ozanimod, and now long-term extension."

Video

[VIRTUAL] Analysis of RP-101074 protective capacities on retinal neurodegeneration and visual function in the non-inflammatory animal model of light-induced photoreceptor loss (ECTRIMS 2021) - "The pupil of the eyes was dilated with 0.5% Tropicamide / 2.5% Phenylephrine before irradiation, and an eye gel was applied to both eyes to prevent dehydration and cataract formation during irradiation. RP-101074 might act not only through immunomodulation but also exerts neuroprotective effects in the preclinical Li-PRL model. References: Kappos, L., Bar-Or, A., Cree, B.A.C., Fox, R.J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D.L., Arnould, S., Scherz, T., Wolf, C., Wallström, E., Dahlke, F., EXPAND Clinical Investigators, 2018. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study."

Preclinical • Cataract • CNS Disorders • Immune Modulation • Immunology • Inflammation • Multiple Sclerosis • Ophthalmology

[VIRTUAL] Analysis of RP-101074 protective capacities on retinal neurodegeneration and visual function in the non-inflammatory animal model of light-induced photoreceptor loss (ECTRIMS 2021) - "The pupil of the eyes was dilated with 0.5% Tropicamide / 2.5% Phenylephrine before irradiation, and an eye gel was applied to both eyes to prevent dehydration and cataract formation during irradiation. RP-101074 might act not only through immunomodulation but also exerts neuroprotective effects in the preclinical Li-PRL model. References: Kappos, L., Bar-Or, A., Cree, B.A.C., Fox, R.J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D.L., Arnould, S., Scherz, T., Wolf, C., Wallström, E., Dahlke, F., EXPAND Clinical Investigators, 2018. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study."

Preclinical • Cataract • CNS Disorders • Immune Modulation • Immunology • Inflammation • Multiple Sclerosis • Ophthalmology